Axsome Therapeutics Files 8-K for Shareholder Votes & Exhibits

TL;DR

AXSM filed an 8-K for shareholder votes and financials - check for details.

AI Summary

Axsome Therapeutics, Inc. filed an 8-K on June 7, 2024, to report on matters submitted to a vote of security holders and to file financial statements and exhibits. The filing does not contain specific details on the votes or financial figures within the provided text.

Why It Matters

This filing indicates important corporate actions and disclosures, including shareholder votes and financial reporting, which are crucial for investors to understand the company's governance and financial health.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate events and financial statements, not indicating any immediate negative developments.

Key Players & Entities

• Axsome Therapeutics, Inc. (company) — Registrant
• June 07, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• One World Trade Center, 22nd Floor (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market

Filing Documents

• axsm-20240607.htm (8-K) — 74KB
• 0000950170-24-071960.txt ( ) — 183KB
• axsm-20240607.xsd (EX-101.SCH) — 23KB
• axsm-20240607_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the 2024 Annual Meeting of Stockholders of Axsome Therapeutics, Inc. (the "Company") held on June 7, 2024 (the "Annual Meeting"), the following proposals were submitted to the stockholders of the Company: Proposal 1: The election of two directors to serve as Class III directors until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified; Proposal 2: The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024; and Proposal 3: The approval, on a non-binding advisory basis, the compensation of the Company's named executive officers. For more information about the foregoing proposals, see the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 26, 2024 (the "Proxy Statement"). Of the 47,493,320 shares of the Company's common stock entitled to vote at the Annual Meeting, 39,921,787 shares, or approximately 84.06%, were represented at the meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such proposal is set forth below: Proposal 1: Election of Class III Directors. The Company's stockholders elected the following directors to serve as Class III directors until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the Class III directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Herriot Tabuteau, M.D. 33,257,792 526,545 6,137,450 Mark Coleman, M.D. 27,121,859 6,662,478 6,137,450 Proposal 2: Ratification of Appointment of Deloitte & Touche LLP. The Company's stockholders ratified the appointment of Deloitte

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Dated: June 11, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Herriot Tabuteau, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR